Persistent abnormal dilatation of the bronchi.
Radiography of the bronchial tree after injection of a contrast medium.
Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus.
Conditions caused by abnormal CILIA movement in the body, usually causing KARTAGENER SYNDROME, chronic respiratory disorders, chronic SINUSITIS, and chronic OTITIS. Abnormal ciliary beating is likely due to defects in any of the 200 plus ciliary proteins, such as missing motor enzyme DYNEIN arms.
Hypersensitivity reaction (ALLERGIC REACTION) to fungus ASPERGILLUS in an individual with long-standing BRONCHIAL ASTHMA. It is characterized by pulmonary infiltrates, EOSINOPHILIA, elevated serum IMMUNOGLOBULIN E, and skin reactivity to Aspergillus antigen.
Expectoration or spitting of blood originating from any part of the RESPIRATORY TRACT, usually from hemorrhage in the lung parenchyma (PULMONARY ALVEOLI) and the BRONCHIAL ARTERIES.
A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers.
An autosomal recessive disorder characterized by a triad of DEXTROCARDIA; INFERTILITY; and SINUSITIS. The syndrome is caused by mutations of DYNEIN genes encoding motility proteins which are components of sperm tails, and CILIA in the respiratory and the reproductive tracts.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
The volume of air that is exhaled by a maximal expiration following a maximal inspiration.
The viscous secretion of mucous membranes. It contains mucin, white blood cells, water, inorganic salts, and exfoliated cells.
Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.
A pathologic process consisting in the formation of pus.
Infections with bacteria of the genus PSEUDOMONAS.
Pathological processes involving any part of the LUNG.

A pilot study of low-dose erythromycin in bronchiectasis. (1/518)

Patients with bronchiectasis suffer from sputum production, recurrent exacerbations, and progressive airway destruction. Erythromycin is effective in diffuse panbronchiolitis, another suppurative airway disorder, although its efficacy is unknown in idiopathic bronchiectasis. A double-blind placebo-controlled study was therefore conducted to evaluate the effects of 8-week administration of low dose erythromycin (500 mg b.i.d.) in steady-state idiopathic bronchiectasis. Patients in the erythromycin group (n=11, 8 female, mean age 50+/-15 yrs), but not the placebo group (n=10, 8 female, mean age 59+/-16 yrs) had significantly improved forced expiratory volume in one second, forced vital capacity and 24-h sputum volume after 8 weeks (p<0.05). There was no parallel improvement in sputum pathogens, leukocytes, interleukin (IL)-1alpha and IL-8, tumour necrosis factor-alpha, or leukotriene B4. The results of this pilot study show that low-dose erythromycin improves lung function and sputum volume in bronchiectasis. Further studies are indicated to evaluate the efficacy of long-term erythromycin therapy in bronchiectasis.  (+info)

Degradation of porstaglandin F2alpha in the human pulmonary circulation. (2/518)

Degradation of prostaglandins (PGs) during passage through the human pulmonary circulation was investigated by measuring the transpulmonary plasma PGF2 alpha difference during continuous intravenous infusion of PGF2 alpha (5-10 mug/min). Seven patients with cardiological disorders and two patients with extensive pulmonary abnormalities were investigated during diagnostic cardiac catheterization. PGF2 alpha levels were measured by radioimmunoassay. The seven cardiac patients were found to have transpulmonary PGF2 alpha differences of 47-88%, indicating metabolism of the PG in the lungs. A patient with extensive bronchiectasis had an apparently normal transpulmonary PGF2alpha difference despite gross abnormalities in routine lung function tests. A patient with primary pulmonary arterial hypertension showed no metabolism of PGF2alpha in the pulmonary circulation. The results show that PG degradation is an aspect of normal lung function and suggest that it becomes imparied when extensive pulmonary vascular damage exists.  (+info)

Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. (3/518)

BACKGROUND: Bronchiectasis is a chronic inflammatory lung disease associated with increased production of oxidants due mostly to neutrophilic inflammation. Induction of heme oxygenase (HO-1) by reactive oxygen species is a general cytoprotective mechanism against oxidative stress. HO-1 catabolises heme to bilirubin, free iron and carbon monoxide (CO). Exhaled CO measurements may therefore reflect an oxidative stress and be clinically useful in the detection and management of inflammatory lung disorders. METHODS: The levels of exhaled CO of 42 non-smoking patients with bronchiectasis treated or not treated with inhaled corticosteroids were compared with CO levels in 37 normal non-smoking subjects. RESULTS: Levels of exhaled CO were raised in patients with bronchiectasis, both those treated with inhaled corticosteroids (n = 27, median 5.5 ppm, 95% CI 5.16 to 7.76) and those not treated with inhaled corticosteroids (n = 15, median 6.0 ppm. 95% CI 4.74 to 11.8), compared with normal subjects (n = 37, median 3.0 ppm, 95% CI 2.79 to 3.81, p = 0.0024). There was no correlation between exhaled CO and HbCO levels (r = 0.42, p = 0.12) in normal subjects (n = 7), nor between the urine cotinine concentration and exhaled CO levels (r = 0.2, p = 0.12). CONCLUSIONS: Increased levels of exhaled CO may reflect induction of HO-1 and oxidative stress in bronchiectasis. Measurement of exhaled CO may be useful in the management of bronchiectasis and possibly other chronic inflammatory lung disorders.  (+info)

Pseudomonas aeruginosa hemolytic phospholipase C suppresses neutrophil respiratory burst activity. (4/518)

Pseudomonas aeruginosa is a persistent pathogen in the airways of patients with cystic fibrosis or bronchiectasis from other causes and appears to have evolved strategies to survive the inflammatory response of the host. We hypothesized that the secreted hemolytic phospholipase C (PLC) of P. aeruginosa (PlcHR) would decrease neutrophil respiratory burst activity. We found that while intact wild-type P. aeruginosa cells stimulated moderate respiratory burst activity from human neutrophils, an isogenic mutant pseudomonas (DeltaHR strain) containing a targeted deletion of the plcHR operon induced a much more robust oxidative burst from neutrophils. In contrast, a second pseudomonas mutant (DeltaN) containing a disruption in the gene encoding the nonhemolytic PLC (PlcN) was not different from the wild type in stimulating neutrophil O2.- production. Readdition of purified PlcHR to the DeltaHR strain suppressed neutrophil O2.- production to levels stimulated by wild-type bacteria. Interestingly, purified PlcHR decreased phorbol myristate acetate (PMA)- but not formyl methionyl-leucyl-proline (fMLP)-induced respiratory burst activity, suggesting interference by PlcHR with a protein kinase C (PKC)-specific signaling pathway. Accordingly, the PKC inhibitor bisindolylmaleimide inhibited the oxidative burst induced by either PMA or intact pseudomonas, but not by fMLP, whereas the p38 kinase inhibitor SB-203580 fully inhibited the respiratory burst induced by fMLP or the PlcHR-replete wild-type bacteria, but not PMA or the PlcHR-deficient DeltaHR bacterial mutant. We conclude that expression of PlcHR by P. aeruginosa suppresses bacterium-induced neutrophil respiratory burst by interfering with a PKC-dependent, non-p38 kinase-dependent pathway.  (+info)

A resuscitated case from asphyxia by large bronchial cast. (5/518)

A 62-year-old woman with bronchiectasis suffered from asphyxia due to a large bronchial cast that obstructed the bronchial tree. Immediate bronchoscopic suction of a bronchial cast of 17 cm in length through the intubated tube relieved the patients without any complications. Large bronchial casts appear to be rare in this century but it should be considered in patients with acute exacerbation of excessive sputa not only in patients with asthma or allergy but also in patients with respiratory tract infection.  (+info)

Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis. (6/518)

PCR fingerprinting was used for the epidemiological investigation of 64 Pseudomonas aeruginosa isolates collected from 16 chronic bronchiectasis patients without cystic fibrosis: 56% of the patients harbored one clone, 12.5% carried a single major type with minor variants, and 31.5% carried two clones. Only a minority of the acquisitions of antibiotic resistance was related to the acquisition of exogenous strains. Mucoid and nonmucoid sets of isolates did not display any consistent differences in their patterns. The genetic similarity among the clones ranged from 10 to 69%. Cross-infection or common-source exposure did not appear to have occurred.  (+info)

A possible mechanism of primary ciliary dyskinesia: a case of a segmental defect in ciliary microtubules. (7/518)

We report here a 13-year-old woman with cough, sputum and fever. The patient had both chronic sinusitis and bronchitis. Chest X-ray and computed tomographic scan of the chest revealed mucous bronchial filling and bronchiectasia in bronchi of bilateral lower lobes, right middle lobe and left upper lobe. Aerosol inhalation scintigraphy with 99mTechnetium demonstrated delays of the discharged tracer. On the basis of these findings, primary ciliary dyskinesia was suggested. This was confirmed by the findings from nasal biopsy with transmission electron microscopy where all of the microtubules were segmentally defected near the basal body in the cilia. On the basis of these findings, we diagnosed the patient with primary ciliary dyskinesia which may be due, at least in part, to segmental defect of ciliary microtubules.  (+info)

Respiratory epithelial ion transport in patients with disseminated bronchiectasis. (8/518)

The nosological limits between disseminated bronchiectasis and cystic fibrosis (CF) remain unclear. In patients with isolated congenital bilateral absence of the vas deferens, a forme fruste of the CF disease, a normal baseline nasal transepithelial potential difference (PD) but an impaired response to pharmacological interventions have been reported. The purpose of the present study was to explore ion transport in respiratory epithelium from patients with disseminated bronchiectasis. The PD under both baseline and pharmacological interventions was investigated in 13 healthy subjects, six patients with genetically proven CF and 15 patients with disseminated bronchiectasis as confirmed by computed tomography scan. Baseline PD was similar in the control and bronchiectasis groups but, as expected, was significantly more negative in the CF group. Patients with bronchiectasis responded to pharmacological tests (sequential perfusion with amiloride, chloride-free solution, isoprenaline and uridine triphosphate (UTP) similarly to healthy subjects. In contrast, CF patients exhibited an increased response to amiloride and an impaired response to chloride-free solution and isoprenaline. The data show that patients with disseminated bronchiectasis exhibit normal electrophysiological properties in their nasal epithelium. Nasal transepithelial potential difference including pharmacological tests may appear a valuable diagnostic procedure for cystic fibrosis with disseminated bronchiectasis.  (+info)

Bronchiectasis is a medical condition characterized by permanent, abnormal widening and thickening of the walls of the bronchi (the airways leading to the lungs). This can lead to recurrent respiratory infections, coughing, and the production of large amounts of sputum. The damage to the airways is usually irreversible and can be caused by various factors such as bacterial or viral infections, genetic disorders, immune deficiencies, or exposure to environmental pollutants. In some cases, the cause may remain unknown. Treatment typically includes chest physiotherapy, bronchodilators, antibiotics, and sometimes surgery.

Bronchography is a medical imaging technique that involves the injection of a contrast material into the airways (bronchi) of the lungs, followed by X-ray imaging to produce detailed pictures of the bronchial tree. This diagnostic procedure was commonly used in the past to identify abnormalities such as narrowing, blockages, or inflammation in the airways, but it has largely been replaced by newer, less invasive techniques like computed tomography (CT) scans and bronchoscopy.

The process of bronchography involves the following steps:

1. The patient is sedated or given a local anesthetic to minimize discomfort during the procedure.
2. A radiopaque contrast material is introduced into the bronchi through a catheter that is inserted into the trachea, either via a nostril or through a small incision in the neck.
3. Once the contrast material has been distributed throughout the bronchial tree, X-ray images are taken from various angles to capture detailed views of the airways.
4. The images are then analyzed by a radiologist to identify any abnormalities or irregularities in the structure and function of the bronchi.

Although bronchography is considered a relatively safe procedure, it does carry some risks, including allergic reactions to the contrast material, infection, and bleeding. Additionally, the use of ionizing radiation during X-ray imaging should be carefully weighed against the potential benefits of the procedure.

Sputum is defined as a mixture of saliva and phlegm that is expelled from the respiratory tract during coughing, sneezing or deep breathing. It can be clear, mucoid, or purulent (containing pus) depending on the underlying cause of the respiratory issue. Examination of sputum can help diagnose various respiratory conditions such as infections, inflammation, or other lung diseases.

Ciliary motility disorders are a group of rare genetic conditions that affect the function of cilia, which are tiny hair-like structures on the surface of cells in the body. Cilia play an important role in moving fluids and particles across the cell surface, including the movement of mucus and other substances in the respiratory system, the movement of eggs and sperm in the reproductive system, and the movement of fluid in the inner ear.

Ciliary motility disorders are caused by mutations in genes that are responsible for the proper functioning of cilia. These mutations can lead to abnormalities in the structure or function of cilia, which can result in a range of symptoms depending on the specific disorder and the parts of the body that are affected.

Some common symptoms of ciliary motility disorders include recurrent respiratory infections, chronic sinusitis, hearing loss, infertility, and situs inversus, a condition in which the major organs are reversed or mirrored from their normal positions. There are several different types of ciliary motility disorders, including primary ciliary dyskinesia, Kartagener syndrome, and immotile cilia syndrome.

Treatment for ciliary motility disorders typically involves addressing the specific symptoms and underlying causes of the disorder. This may include antibiotics to treat respiratory infections, surgery to correct structural abnormalities, or assisted reproductive technologies to help with infertility.

Allergic bronchopulmonary aspergillosis (ABPA) is a medical condition characterized by an hypersensitivity reaction to the fungus Aspergillus species, most commonly A. fumigatus. It primarily affects the airways and lung tissue. The immune system overreacts to the presence of the fungus, leading to inflammation and damage in the lungs.

The main symptoms of ABPA include wheezing, coughing, production of thick mucus, shortness of breath, and chest tightness. These symptoms are similar to those seen in asthma and other respiratory conditions. Some people with ABPA may also experience fever, weight loss, and fatigue.

Diagnosis of ABPA typically involves a combination of clinical evaluation, imaging studies (such as chest X-rays or CT scans), and laboratory tests (such as blood tests or sputum cultures) to detect the presence of Aspergillus species and elevated levels of certain antibodies.

Treatment for ABPA usually involves a combination of corticosteroids to reduce inflammation and antifungal medications to eradicate the Aspergillus infection. In some cases, immunomodulatory therapies may also be used to help regulate the immune system's response to the fungus.

It is important to note that ABPA can lead to serious complications if left untreated, including bronchiectasis (permanent enlargement of the airways), pulmonary fibrosis (scarring of the lung tissue), and respiratory failure. Therefore, prompt diagnosis and treatment are essential for managing this condition.

Hemoptysis is the medical term for coughing up blood that originates from the lungs or lower respiratory tract. It can range in severity from streaks of blood mixed with mucus to large amounts of pure blood. Hemoptysis may be a sign of various underlying conditions, such as bronchitis, pneumonia, tuberculosis, cancer, or blood disorders. Immediate medical attention is required when hemoptysis occurs, especially if it's in significant quantities, to determine the cause and provide appropriate treatment.

Mucociliary clearance is a vital defense mechanism of the respiratory system that involves the coordinated movement of tiny hair-like structures called cilia, which are present on the surface of the respiratory epithelium, and the mucus layer. This mechanism helps to trap inhaled particles, microorganisms, and other harmful substances and move them away from the lungs towards the upper airways, where they can be swallowed or coughed out.

The cilia beat in a coordinated manner, moving in a wave-like motion to propel the mucus layer upwards. This continuous movement helps to clear the airways of any debris and maintain a clean and healthy respiratory system. Mucociliary clearance plays an essential role in preventing respiratory infections and maintaining lung function. Any impairment in this mechanism, such as due to smoking or certain respiratory conditions, can increase the risk of respiratory infections and other related health issues.

Kartagener Syndrome is a rare genetic disorder that primarily affects the respiratory system. It is characterized by the triad of chronic sinusitis, bronchiectasis (damage and widening of the airways in the lungs), and situs inversus totalis - a condition where the major visceral organs are mirrored or reversed from their normal positions.

In Kartagener Syndrome, the cilia (tiny hair-like structures) lining the respiratory tract are abnormal or dysfunctional, which impairs their ability to clear mucus and other particles. This leads to recurrent respiratory infections, bronchiectasis, and ultimately, progressive lung damage.

The condition is inherited as an autosomal recessive trait, meaning that an individual must inherit two copies of the defective gene - one from each parent - to develop the syndrome. Kartagener Syndrome is a subtype of primary ciliary dyskinesia (PCD), a group of disorders affecting ciliary structure and function.

Cystic fibrosis (CF) is a genetic disorder that primarily affects the lungs and digestive system. It is caused by mutations in the CFTR gene, which regulates the movement of salt and water in and out of cells. When this gene is not functioning properly, thick, sticky mucus builds up in various organs, leading to a range of symptoms.

In the lungs, this mucus can clog the airways, making it difficult to breathe and increasing the risk of lung infections. Over time, lung damage can occur, which may lead to respiratory failure. In the digestive system, the thick mucus can prevent the release of digestive enzymes from the pancreas, impairing nutrient absorption and leading to malnutrition. CF can also affect the reproductive system, liver, and other organs.

Symptoms of cystic fibrosis may include persistent coughing, wheezing, lung infections, difficulty gaining weight, greasy stools, and frequent greasy diarrhea. The severity of the disease can vary significantly among individuals, depending on the specific genetic mutations they have inherited.

Currently, there is no cure for cystic fibrosis, but treatments are available to help manage symptoms and slow the progression of the disease. These may include airway clearance techniques, medications to thin mucus, antibiotics to treat infections, enzyme replacement therapy, and a high-calorie, high-fat diet. Lung transplantation is an option for some individuals with advanced lung disease.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Respiratory Function Tests (RFTs) are a group of medical tests that measure how well your lungs take in and exhale air, and how well they transfer oxygen and carbon dioxide into and out of your blood. They can help diagnose certain lung disorders, measure the severity of lung disease, and monitor response to treatment.

RFTs include several types of tests, such as:

1. Spirometry: This test measures how much air you can exhale and how quickly you can do it. It's often used to diagnose and monitor conditions like asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases.
2. Lung volume testing: This test measures the total amount of air in your lungs. It can help diagnose restrictive lung diseases, such as pulmonary fibrosis or sarcoidosis.
3. Diffusion capacity testing: This test measures how well oxygen moves from your lungs into your bloodstream. It's often used to diagnose and monitor conditions like pulmonary fibrosis, interstitial lung disease, and other lung diseases that affect the ability of the lungs to transfer oxygen to the blood.
4. Bronchoprovocation testing: This test involves inhaling a substance that can cause your airways to narrow, such as methacholine or histamine. It's often used to diagnose and monitor asthma.
5. Exercise stress testing: This test measures how well your lungs and heart work together during exercise. It's often used to diagnose lung or heart disease.

Overall, Respiratory Function Tests are an important tool for diagnosing and managing a wide range of lung conditions.

Forced Expiratory Volume (FEV) is a medical term used to describe the volume of air that can be forcefully exhaled from the lungs in one second. It is often measured during pulmonary function testing to assess lung function and diagnose conditions such as chronic obstructive pulmonary disease (COPD) or asthma.

FEV is typically expressed as a percentage of the Forced Vital Capacity (FVC), which is the total volume of air that can be exhaled from the lungs after taking a deep breath in. The ratio of FEV to FVC is used to determine whether there is obstruction in the airways, with a lower ratio indicating more severe obstruction.

There are different types of FEV measurements, including FEV1 (the volume of air exhaled in one second), FEV25-75 (the average volume of air exhaled during the middle 50% of the FVC maneuver), and FEV0.5 (the volume of air exhaled in half a second). These measurements can provide additional information about lung function and help guide treatment decisions.

A cough is a reflex action that helps to clear the airways of irritants, foreign particles, or excess mucus or phlegm. It is characterized by a sudden, forceful expulsion of air from the lungs through the mouth and nose. A cough can be acute (short-term) or chronic (long-term), and it can be accompanied by other symptoms such as chest pain, shortness of breath, or fever. Coughing can be caused by various factors, including respiratory infections, allergies, asthma, environmental pollutants, gastroesophageal reflux disease (GERD), and chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and bronchitis. In some cases, a cough may be a symptom of a more serious underlying condition, such as heart failure or lung cancer.

Bronchitis is a medical condition characterized by inflammation of the bronchi, which are the large airways that lead to the lungs. This inflammation can cause a variety of symptoms, including coughing, wheezing, chest tightness, and shortness of breath. Bronchitis can be either acute or chronic.

Acute bronchitis is usually caused by a viral infection, such as a cold or the flu, and typically lasts for a few days to a week. Symptoms may include a productive cough (coughing up mucus or phlegm), chest discomfort, and fatigue. Acute bronchitis often resolves on its own without specific medical treatment, although rest, hydration, and over-the-counter medications to manage symptoms may be helpful.

Chronic bronchitis, on the other hand, is a long-term condition that is characterized by a persistent cough with mucus production that lasts for at least three months out of the year for two consecutive years. Chronic bronchitis is typically caused by exposure to irritants such as cigarette smoke, air pollution, or occupational dusts and chemicals. It is often associated with chronic obstructive pulmonary disease (COPD), which includes both chronic bronchitis and emphysema.

Treatment for chronic bronchitis may include medications to help open the airways, such as bronchodilators and corticosteroids, as well as lifestyle changes such as smoking cessation and avoiding irritants. In severe cases, oxygen therapy or lung transplantation may be necessary.

Vital capacity (VC) is a term used in pulmonary function tests to describe the maximum volume of air that can be exhaled after taking a deep breath. It is the sum of inspiratory reserve volume, tidal volume, and expiratory reserve volume. In other words, it's the total amount of air you can forcibly exhale after inhaling as deeply as possible. Vital capacity is an important measurement in assessing lung function and can be reduced in conditions such as chronic obstructive pulmonary disease (COPD), asthma, and other respiratory disorders.

Mucus is a viscous, slippery secretion produced by the mucous membranes that line various body cavities such as the respiratory and gastrointestinal tracts. It serves to lubricate and protect these surfaces from damage, infection, and foreign particles. Mucus contains water, proteins, salts, and other substances, including antibodies, enzymes, and glycoproteins called mucins that give it its characteristic gel-like consistency.

In the respiratory system, mucus traps inhaled particles such as dust, allergens, and pathogens, preventing them from reaching the lungs. The cilia, tiny hair-like structures lining the airways, move the mucus upward toward the throat, where it can be swallowed or expelled through coughing or sneezing. In the gastrointestinal tract, mucus helps protect the lining of the stomach and intestines from digestive enzymes and other harmful substances.

Excessive production of mucus can occur in various medical conditions such as allergies, respiratory infections, chronic lung diseases, and gastrointestinal disorders, leading to symptoms such as coughing, wheezing, nasal congestion, and diarrhea.

Common Variable Immunodeficiency (CVID) is a type of primary immunodeficiency disorder characterized by reduced levels of immunoglobulins (also known as antibodies) in the blood, which makes an individual more susceptible to infections. The term "common" refers to its prevalence compared to other types of immunodeficiencies, and "variable" indicates the variability in the severity and types of symptoms among affected individuals.

Immunoglobulins are proteins produced by the immune system to help fight off infections caused by bacteria, viruses, and other pathogens. In CVID, there is a deficiency in the production or function of these immunoglobulins, particularly IgG, IgA, and/or IgM. This results in recurrent infections, chronic inflammation, and an increased risk of developing autoimmune disorders and cancer.

Symptoms of CVID can include:

1. Recurrent sinus, ear, and lung infections
2. Gastrointestinal issues, such as diarrhea, bloating, and malabsorption
3. Autoimmune disorders, like rheumatoid arthritis, lupus, or inflammatory bowel disease
4. Increased risk of certain cancers, particularly lymphomas
5. Fatigue and poor growth in children
6. Delayed puberty in adolescents
7. Lung damage due to recurrent infections
8. Poor response to vaccinations

The exact cause of CVID is not fully understood, but it is believed to be related to genetic factors. In some cases, a family history of immunodeficiency disorders may be present. Diagnosis typically involves blood tests to measure immunoglobulin levels and other immune system components, as well as genetic testing to identify any known genetic mutations associated with CVID. Treatment usually consists of regular infusions of immunoglobulins to replace the missing antibodies and help prevent infections.

Suppuration is the process of forming or discharging pus. It is a condition that results from infection, tissue death (necrosis), or injury, where white blood cells (leukocytes) accumulate to combat the infection and subsequently die, forming pus. The pus consists of dead leukocytes, dead tissue, debris, and microbes (bacteria, fungi, or protozoa). Suppuration can occur in various body parts such as the lungs (empyema), brain (abscess), or skin (carbuncle, furuncle). Treatment typically involves draining the pus and administering appropriate antibiotics to eliminate the infection.

Pseudomonas infections are infections caused by the bacterium Pseudomonas aeruginosa or other species of the Pseudomonas genus. These bacteria are gram-negative, opportunistic pathogens that can cause various types of infections, including respiratory, urinary tract, gastrointestinal, dermatological, and bloodstream infections.

Pseudomonas aeruginosa is a common cause of healthcare-associated infections, particularly in patients with weakened immune systems, chronic lung diseases, or those who are hospitalized for extended periods. The bacteria can also infect wounds, burns, and medical devices such as catheters and ventilators.

Pseudomonas infections can be difficult to treat due to the bacteria's resistance to many antibiotics. Treatment typically involves the use of multiple antibiotics that are effective against Pseudomonas aeruginosa. In severe cases, intravenous antibiotics or even hospitalization may be necessary.

Prevention measures include good hand hygiene, contact precautions for patients with known Pseudomonas infections, and proper cleaning and maintenance of medical equipment.

Lung diseases refer to a broad category of disorders that affect the lungs and other structures within the respiratory system. These diseases can impair lung function, leading to symptoms such as coughing, shortness of breath, chest pain, and wheezing. They can be categorized into several types based on the underlying cause and nature of the disease process. Some common examples include:

1. Obstructive lung diseases: These are characterized by narrowing or blockage of the airways, making it difficult to breathe out. Examples include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and cystic fibrosis.
2. Restrictive lung diseases: These involve stiffening or scarring of the lungs, which reduces their ability to expand and take in air. Examples include idiopathic pulmonary fibrosis, sarcoidosis, and asbestosis.
3. Infectious lung diseases: These are caused by bacteria, viruses, fungi, or parasites that infect the lungs. Examples include pneumonia, tuberculosis, and influenza.
4. Vascular lung diseases: These affect the blood vessels in the lungs, impairing oxygen exchange. Examples include pulmonary embolism, pulmonary hypertension, and chronic thromboembolic pulmonary hypertension (CTEPH).
5. Neoplastic lung diseases: These involve abnormal growth of cells within the lungs, leading to cancer. Examples include small cell lung cancer, non-small cell lung cancer, and mesothelioma.
6. Other lung diseases: These include interstitial lung diseases, pleural effusions, and rare disorders such as pulmonary alveolar proteinosis and lymphangioleiomyomatosis (LAM).

It is important to note that this list is not exhaustive, and there are many other conditions that can affect the lungs. Proper diagnosis and treatment of lung diseases require consultation with a healthcare professional, such as a pulmonologist or respiratory therapist.

No FAQ available that match "bronchiectasis"

No images available that match "bronchiectasis"